Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2020-07-30 | CTLT | Catalent, Inc. | Lucier Gregory T | Dir | S - Sale | $90.09 | -24,000 | 21,989 | -52% | -$2,162,160 | ||||||
| M | 2020-07-30 | RZLT | Rezolute, Inc. | Handok, Inc. | 10% | P - Purchase | $0.32 | +375,000 | 94,589,587 | 0% | +$118,963 | |||||
| D | 2020-07-29 | BGNE | Beigene, Ltd. | Huang Jane | CMO, Hematology | S - Sale+OE | $209.93 | -3,000 | 326,247 | -1% | -$629,787 | |||||
| D | 2020-07-24 | GNCA | Genocea Biosciences, Inc. | Glaxosmithkline Plc | 10% | P - Purchase | $2.25 | +1,260,504 | 4,626,389 | +37% | +$2,836,134 | |||||
2020-07-28 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $17.99 | +4,105 | 18,032,859 | 0% | +$73,849 | ||||||
| D | 2020-07-29 | CYTK | Cytokinetics Inc | Schlossberg Mark A | SVP - Legal, GC | S - Sale+OE | $23.07 | -10,000 | 30,000 | -25% | -$230,728 | |||||
| D | 2020-07-28 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $23.77 | -5,000 | 309,034 | -2% | -$118,829 | |||||
2020-07-28 | RTRX | Retrophin, Inc. | Rosenberg Noah L. | Chief Medical Officer | S - Sale | $20.49 | -870 | 26,055 | -3% | -$17,826 | ||||||
2020-07-28 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $17.99 | +4,105 | 18,032,859 | 0% | +$73,849 | ||||||
| M | 2020-07-28 | TYME | Tyme Technologies, Inc. | Hoffman Steve | CEO, 10% | S - Sale | $1.21 | -95,500 | 26,345,949 | 0% | -$115,555 | |||||
2020-07-28 | HGEN | Humanigen, Inc | Nomis Bay Ltd. | 10% | S - Sale | $5.66 | -10,000 | 32,679,270 | 0% | -$56,550 | ||||||
| M | 2020-07-28 | RZLT | Rezolute, Inc. | Handok, Inc. | 10% | P - Purchase | $0.33 | +250,000 | 94,214,587 | 0% | +$82,575 | |||||
| D | 2020-07-27 | FOLD | Amicus Therapeutics, Inc. | Barth Jay | Chief Medical Officer | S - Sale+OE | $15.05 | -30,000 | 163,224 | -16% | -$451,377 | |||||
2020-07-27 | VNDA | Vanda Pharmaceuticals Inc. | Jones Aranthan II | Chief Corp. Affairs Officer | S - Sale | $10.62 | -7,313 | 82,687 | -8% | -$77,631 | ||||||
| M | 2020-07-27 | CCXI | Chemocentryx, Inc. | Vifor (International) Ltd | 10% | S - Sale | $52.97 | -162,408 | 9,331,826 | -2% | -$8,602,072 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Novo Holdings A/s | 10% | P - Purchase | $16.00 | +375,000 | 2,569,379 | +17% | +$6,000,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Sanofi | 10% | P - Purchase | $16.00 | +81,250 | 520,125 | +19% | +$1,300,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Rock Springs Capital Management LP | 10% | P - Purchase | $16.00 | +600,000 | 1,067,884 | +128% | +$9,600,000 | |||||
2020-07-24 | FGEN | Fibrogen Inc | Yu K Peony | Chief Medical Officer | S - Sale | $42.35 | -3,351 | 205,576 | -2% | -$141,915 | ||||||
2020-07-28 | JNJ | Johnson & Johnson | McEvoy Ashley | EVP, WW Chair, Medical Devices | S - Sale | $147.47 | -29,000 | 24,433 | -54% | -$4,276,630 | ||||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $16.00 | +600,000 | 2,003,653 | +43% | +$9,600,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Sonsini Peter W. | 10% | P - Purchase | $16.00 | +250,000 | 2,437,689 | +11% | +$4,000,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Sandell Scott D | 10% | P - Purchase | $16.00 | +250,000 | 2,437,689 | +11% | +$4,000,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Makower Joshua | 10% | P - Purchase | $16.00 | +250,000 | 2,437,689 | +11% | +$4,000,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Makhzoumi Mohamad | 10% | P - Purchase | $16.00 | +250,000 | 2,437,689 | +11% | +$4,000,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Florence Anthony A. Jr. | 10% | P - Purchase | $16.00 | +250,000 | 2,437,689 | +11% | +$4,000,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Baskett Forest | 10% | P - Purchase | $16.00 | +250,000 | 2,437,689 | +11% | +$4,000,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | New Enterprise Associates 15, L.P. | 10% | P - Purchase | $16.00 | +250,000 | 2,437,689 | +11% | +$4,000,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Longitude Capital Partners Iii, LLC | 10% | P - Purchase | $16.00 | +625,000 | 2,819,379 | +28% | +$10,000,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Pivotal Bioventure Partners Fund I, L.P. | 10% | P - Purchase | $16.00 | +187,500 | 1,591,154 | +13% | +$3,000,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Hopfner Robert Lorne | Dir, 10% | P - Purchase | $16.00 | +187,500 | 1,591,154 | +13% | +$3,000,000 | |||||
| D | 2020-07-28 | INZY | Inozyme Pharma, Inc. | Sofinnova Venture Partners X, L.P. | 10% | P - Purchase | $16.00 | +437,500 | 2,028,308 | +28% | +$7,000,000 | |||||
| M | 2020-07-24 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $17.93 | +72,583 | 18,028,754 | 0% | +$1,301,643 | |||||
| M | 2020-07-24 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $17.93 | +72,583 | 18,028,754 | 0% | +$1,301,643 | |||||
| D | 2020-07-27 | URGN | Urogen Pharma Ltd. | Pfreundschuh Peter P. | CFO | S - Sale+OE | $23.51 | -141 | 7,355 | -2% | -$3,315 | |||||
| D | 2020-07-27 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale+OE | $23.51 | -70 | 18,543 | 0% | -$1,646 | |||||
| A | 2020-07-27 | TYME | Tyme Technologies, Inc. | Demurjian Michael | 10% | S - Sale | $1.22 | -20,000 | 25,418,546 | 0% | -$24,400 | |||||
| D | 2020-07-27 | MGNX | Macrogenics Inc | Risser Eric Blasius | SVP, Chief Business Officer | S - Sale+OE | $25.47 | -4,489 | 44,468 | -9% | -$114,319 | |||||
2020-07-27 | TYME | Tyme Technologies, Inc. | Demurjian Michael | 10% | S - Sale | $1.22 | -20,000 | 25,418,546 | 0% | -$24,430 | ||||||
| D | 2020-07-28 | ANNX | Annexon, Inc. | Bain Capital Life Sciences Investors, LLC | 10% | P - Purchase | $17.00 | +400,000 | 3,241,628 | +14% | +$6,800,000 | |||||
2020-07-28 | ANNX | Annexon, Inc. | Lew Jennifer | EVP, CFO | P - Purchase | $17.00 | +2,000 | 2,000 | New | +$34,000 | ||||||
| D | 2020-07-28 | ANNX | Annexon, Inc. | Satter Muneer A | Dir | P - Purchase | $17.00 | +200,000 | 1,954,978 | +11% | +$3,400,000 | |||||
| D | 2020-07-28 | ANNX | Annexon, Inc. | Flynn James E | Possible Member of 10% Group, 10% | P - Purchase | $17.00 | +700,000 | 1,617,828 | +76% | +$11,900,000 | |||||
| M | 2020-07-24 | RZLT | Rezolute, Inc. | Handok, Inc. | 10% | P - Purchase | $0.33 | +250,000 | 93,964,587 | 0% | +$81,500 | |||||
2020-07-24 | ACER | Acer Therapeutics Inc. | Aselage Steve | Dir | P - Purchase | $3.50 | +45,000 | 63,905 | +238% | +$157,500 | ||||||
2020-07-24 | ACER | Acer Therapeutics Inc. | Dunn John Michael | Dir | P - Purchase | $3.50 | +21,428 | 27,380 | +360% | +$74,998 | ||||||
2020-07-24 | ACER | Acer Therapeutics Inc. | Joseph Donald | GC, Secy | P - Purchase | $3.50 | +14,285 | 14,285 | New | +$49,998 | ||||||
2020-07-24 | ACER | Acer Therapeutics Inc. | Schelling Chris | Pres, CEO, 10% | P - Purchase | $3.50 | +142,857 | 1,892,857 | +8% | +$500,000 | ||||||
2020-07-24 | RAPT | Rapt Therapeutics, Inc. | Robbins Wendye | Dir | P - Purchase | $22.47 | +900 | 5,450 | +20% | +$20,225 | ||||||
2020-07-23 | ABUS | Arbutus Biopharma Corp | McElhaugh Michael J. | Chief Business Officer | S - Sale | $5.01 | -20,000 | 1,367,457 | -1% | -$100,200 | ||||||
| D | 2020-07-23 | ABT | Abbott Laboratories | Novakovic Phebe N | Dir | S - Sale+OE | $100.78 | -933 | 31,113 | -3% | -$94,026 | |||||
| M | 2020-07-22 | CCXI | Chemocentryx, Inc. | Vifor (International) Ltd | 10% | S - Sale | $54.62 | -133,074 | 9,494,234 | -1% | -$7,267,902 | |||||
2020-07-22 | MACK | Merrimack Pharmaceuticals Inc | Crocker Gary L | See Remarks | S - Sale | $3.08 | -193,509 | 0 | -100% | -$596,465 | ||||||
2020-07-22 | MACK | Merrimack Pharmaceuticals Inc | Andersen Eric | See remarks | P - Purchase | $3.11 | +177,274 | 227,182 | +355% | +$552,086 | ||||||
2020-07-22 | MACK | Merrimack Pharmaceuticals Inc | Levy Noah G. | See remarks | P - Purchase | $3.11 | +177,274 | 580,515 | +44% | +$552,087 | ||||||
| A | 2020-06-29 | HOOK | Hookipa Pharma Inc. | Sofinnova Capital VI Fcpr | 10% | S - Sale | $11.78 | -3,280 | 3,960,574 | 0% | -$38,628 | |||||
2020-07-22 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, CFO, MD | S - Sale | $42.31 | -5,626 | 297,914 | -2% | -$238,025 | ||||||
| M | 2020-07-22 | RZLT | Rezolute, Inc. | Handok, Inc. | 10% | P - Purchase | $0.29 | +437,000 | 93,714,587 | 0% | +$127,261 | |||||
| D | 2020-07-22 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $18.00 | +193 | 17,912,171 | 0% | +$3,474 | |||||
| D | 2020-07-22 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | Dir, 10% | P - Purchase | $18.00 | +193 | 17,912,171 | 0% | +$3,474 | |||||
2020-07-22 | FREQ | Frequency Therapeutics, Inc. | Loose Christopher R. | Chief Scientific Officer | S - Sale | $21.51 | -4,500 | 161,782 | -3% | -$96,791 | ||||||
2020-07-22 | ABT | Abbott Laboratories | Austin Roxanne S | Dir | S - Sale | $99.80 | -6,844 | 40,043 | -15% | -$683,038 | ||||||
| D | 2020-07-21 | ABT | Abbott Laboratories | Pederson Michael J | SVP | S - Sale+OE | $98.00 | -23,008 | 71,454 | -24% | -$2,254,784 | |||||
| D | 2020-07-21 | ONCT | Oncternal Therapeutics, Inc. | Kisner Daniel L | Dir | P - Purchase | $2.38 | +10,000 | 10,000 | New | +$23,825 | |||||
| D | 2020-07-21 | ONCT | Oncternal Therapeutics, Inc. | Aker Hazel M | Legal Counsel | P - Purchase | $2.38 | +41,972 | 51,271 | +451% | +$99,998 | |||||
| D | 2020-07-21 | PAND | Pandion Therapeutics, Inc. | Mutz Mitchell | Dir, 10% | P - Purchase | $18.00 | +46,111 | 3,096,084 | +2% | +$829,998 | |||||
| D | 2020-07-21 | ONCT | Oncternal Therapeutics, Inc. | Shanghai Pharmaceutical (Usa) Inc. | 10% | P - Purchase | $2.38 | +1,049,317 | 3,544,431 | +42% | +$2,499,998 | |||||
2020-07-22 | ALBO | Albireo Pharma, Inc. | Duncan Jason | GC, GC | S - Sale | $25.80 | -91 | 4,370 | -2% | -$2,348 | ||||||
2020-07-22 | ALBO | Albireo Pharma, Inc. | Horn Patrick Taylor | Chief Medical Officer | S - Sale | $25.80 | -91 | 4,374 | -2% | -$2,348 | ||||||
| DM | 2020-07-20 | APLT | Applied Therapeutics Inc. | Shendelman Shoshana | Pres, CEO, 10% | S - Sale+OE | $26.68 | -45,000 | 4,884,776 | -1% | -$1,200,789 | |||||
2020-07-20 | GWPH | Gw Pharmaceuticals Plc | Knappertz Volker | Chief Medical Officer | S - Sale | $11.42 | -6,000 | 53,940 | -10% | -$68,520 | ||||||
| DM | 2020-07-20 | AMPH | Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob | EVP Corp Admin Center | S - Sale+OE | $21.14 | -10,164 | 48,455 | -17% | -$214,884 | |||||
2020-07-22 | BGNE | Beigene, Ltd. | Oyler John | CEO | S - Sale | $238.34 | -27,748 | 61,260,703 | 0% | -$6,613,503 | ||||||
| M | 2020-07-20 | BGNE | Beigene, Ltd. | Oyler John | CEO | S - Sale | $251.84 | -55,175 | 61,621,427 | 0% | -$13,895,479 | |||||
2020-07-20 | FREQ | Frequency Therapeutics, Inc. | Marcus Joel S | Dir | P - Purchase | $18.00 | +55,555 | 1,331,430 | +4% | +$999,990 | ||||||
| D | 2020-07-22 | HZNP | Horizon Therapeutics Public Ltd Co | Grey Michael G | Dir | S - Sale+OE | $60.00 | -1,755 | 62,290 | -3% | -$105,300 | |||||
| D | 2020-07-20 | BMRN | Biomarin Pharmaceutical Inc | Fuchs Henry J | Pres, Worldwide R, D | S - Sale+OE | $130.00 | -126,389 | 102,995 | -55% | -$16,430,570 | |||||
2020-07-20 | BGNE | Beigene, Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale | $251.51 | -17,000 | 11,940,989 | 0% | -$4,275,636 | ||||||
| D | 2020-07-21 | REGN | Regeneron Pharmaceuticals, Inc. | Fenimore Christopher R. | VP Controller | S - Sale+OE | $642.04 | -3,709 | 23,623 | -14% | -$2,381,317 | |||||
| D | 2020-07-21 | REGN | Regeneron Pharmaceuticals, Inc. | Landry Robert E | EVP Finance CFO | S - Sale+OE | $647.58 | -391 | 24,871 | -2% | -$253,204 | |||||
| D | 2020-07-21 | PAND | Pandion Therapeutics, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $18.00 | +361,111 | 1,770,023 | +26% | +$6,499,998 | |||||
| D | 2020-07-21 | ALXO | Alx Oncology Holdings Inc | Lsv Associates, LLC | 10% | P - Purchase | $19.00 | +400,000 | 120,212 | -143% | +$7,600,000 | |||||
| D | 2020-07-21 | PAND | Pandion Therapeutics, Inc. | Glaxosmithkline Plc | Dir, 10% | P - Purchase | $18.00 | +361,111 | 2,248,304 | +19% | +$6,499,998 | |||||
| M | 2020-07-20 | IMUX | Immunic, Inc. | Groeppel Manfred | COO | S - Sale | $14.58 | -5,650 | 278,830 | -2% | -$82,355 | |||||
| M | 2020-07-20 | IMUX | Immunic, Inc. | Vitt Daniel | CEO | S - Sale | $14.68 | -6,300 | 362,877 | -2% | -$92,510 | |||||
2020-06-29 | HOOK | Hookipa Pharma Inc. | Sofinnova Capital VI Fcpr | 10% | S - Sale | $11.78 | -3,280 | 3,960,574 | 0% | -$38,628 | ||||||
2020-07-20 | HOOK | Hookipa Pharma Inc. | Sofinnova Capital VI Fcpr | 10% | S - Sale | $11.94 | -12,483 | 3,948,091 | 0% | -$149,102 | ||||||
2020-07-21 | RZLT | Rezolute, Inc. | Handok, Inc. | 10% | P - Purchase | $0.25 | +250,000 | 93,277,587 | 0% | +$63,150 | ||||||
| D | 2020-07-21 | ALXO | Alx Oncology Holdings Inc | Lettmann Jason | Dir, 10% | P - Purchase | $19.00 | +400,000 | 227,432 | -232% | +$7,600,000 | |||||
| D | 2020-07-21 | ALXO | Alx Oncology Holdings Inc | Adelman Robert J | See Remarks, 10% | P - Purchase | $19.00 | +853,000 | 5,829,542 | +17% | +$16,207,000 | |||||
| D | 2020-07-21 | ALXO | Alx Oncology Holdings Inc | Vivo Capital Ix, LLC | 10% | P - Purchase | $19.00 | +975,000 | 185,526 | -123% | +$18,525,000 | |||||
| D | 2020-07-21 | ALXO | Alx Oncology Holdings Inc | Graham G. Walmsley | Dir | P - Purchase | $19.00 | +975,000 | 975,000 | New | +$18,525,000 | |||||
2020-07-21 | ALXO | Alx Oncology Holdings Inc | Hemrajani Rekha | Dir | P - Purchase | $19.00 | +3,000 | 3,000 | New | +$57,000 | ||||||
| D | 2020-07-21 | ALXO | Alx Oncology Holdings Inc | Goodman Corey S | Executive Chairman, 10% | P - Purchase | $19.00 | +850,000 | 515,894 | -254% | +$16,150,000 | |||||
2020-07-20 | TYME | Tyme Technologies, Inc. | Demurjian Michael | 10% | S - Sale | $1.24 | -20,000 | 25,438,546 | 0% | -$24,756 | ||||||
2020-07-21 | ALXO | Alx Oncology Holdings Inc | Pietzke Steffen | VP Fin, Chief Acct Officer | P - Purchase | $19.00 | +3,000 | 3,000 | New | +$57,000 | ||||||
2020-07-21 | ALXO | Alx Oncology Holdings Inc | Garcia Peter S | CFO | P - Purchase | $19.00 | +3,000 | 3,000 | New | +$57,000 | ||||||
| D | 2020-07-21 | PAND | Pandion Therapeutics, Inc. | Polaris Partners Gp Viii, L.L.C. | 10% | P - Purchase | $18.00 | +36,111 | 110,621 | +48% | +$649,998 | |||||
| D | 2020-07-21 | PAND | Pandion Therapeutics, Inc. | Boxer Capital, LLC | 10% | P - Purchase | $18.00 | +722,222 | 2,131,135 | +51% | +$12,999,996 | |||||
| D | 2020-07-21 | PAND | Pandion Therapeutics, Inc. | Carroll Jill | Dir, 10% | P - Purchase | $18.00 | +361,111 | 2,248,304 | +19% | +$6,499,998 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |